Clinicopathology Illustration Treatment Options and Survival in the Patients with Testicular Germ Cell Tumors in Kermanshah Province, Iran

Background: Testicular germ cell tumors (TGCTs) account for only 1% - 2% of all male neoplasma. Objectives: The aim of this study is to evaluate clinicopathological features, treatment options and overall survival (OS) in patients with TGCT in Kermanshah province, Iran. Methods: In this retrospective study, 39 patients that referred to oncology clinic in Kermanshah Province, Iran were included. All patients were diagnosed with TGCT between 2000 and 2014 and completed primary therapy (orchidectomy) than 37 patients was treated with chemotherapy and out of 37 patients, 9 patients were treated with radiotherapy in different parts of body (brain, mediastinal, or retro peritoneal). In the first diagnosis, serum tumor markers such as lactate dehydrogenase, -fetoprotein, and human chorionic gonadotropin had been measured. Statistical analyses, survival and diagrams were performed using the SPSS 19, Prism and Excel 2007, respectively. Results: The mean age at diagnosis for the patients was 34.6 years (ranging 16 - 63 years). We divided the patients to two age groups, twenty-five (64.1%) were placed in age 40 years group. Among nine metastatic patients, metastasis to brain, lung, kidney and lung + liver were 44.44%, 33.34%, 11.11 and 11.11%, respectively. The 5-year OS rate was 77.8%. Twenty-one patients had seminoma (53.8%) and 18 (46.2%) had non-seminoma. Conclusions: First of all, seminoma has a higher percentage in TGCT patients. Second, the mean age in TGCT patients is between 30 and 35 years. Third, in our study, brain metastasis had higher prevalence compared to other studies. At last, the OS in our study was similar to those of other studies.